How FDA’s Lifted Clinical Hold On GH001 At GH Research (GHRS) Has Changed Its Investment Story

• In early January 2026, GH Research PLC reported that the FDA lifted the clinical hold on its GH001 IND, clearing the way for U.S. enrollment after Phase 2b data in treatment-resistant depression showed a meaningful placebo-adjusted improvement in MADRS scores, rapid remission rates, and a favorable safety profile with no serious treatment-related adverse events.

• The company also highlighted GH001's very short median psychoactive experience of about 11 minutes, no psychotherapy requirement, and rapid discharge readiness for nearly all patients, positioning the drug candidate as a potentially practical fit for existing interventional psychiatry settings.

• Next, we will examine how the lifting of the FDA clinical hold on GH001 shapes GH Research's investment narrative and outlook.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

What Is GH Research's Investment Narrative?

For GH Research to make sense as an investment, you really have to believe that GH001 can transition from promising data into a commercially relevant treatment for treatment‑resistant depression, despite the company's lack of revenue and continuing losses. The FDA's decision in early January 2026 to lift the clinical hold on the GH001 IND is a meaningful shift in the near term: it clears the path for U.S. enrollment, aligns development across major regions, and removes a regulatory overhang that had been a key risk. In the short run, the main catalysts now look like clinical execution and any future regulatory feedback, rather than simply resolving the IND hold. At the same time, GH Research remains a single‑asset, pre‑revenue biotech with an unprofitable track record and a volatile share price, so the downside if GH001's path stalls is still significant.

However, investors also need to consider one less comfortable risk around funding and dilution. The analysis detailed in our GH Research valuation report hints at an inflated share price compared to its estimated value.

Exploring Other Perspectives

Two Simply Wall St Community fair values for GH Research span roughly US$3.26 to US$32.61, showing how far apart individual views can be. Set that against a company still loss making with zero revenue and heavily dependent on GH001's progress, and it becomes clear why you might want to explore several alternative viewpoints before forming your own stance.

Explore 2 other fair value estimates on GH Research - why the stock might be worth over 2x more than the current price!